We are launching a new research collaboration with a leading academic oncology institute to advance work on difficult-to-drug solid-tumor targets. The program will combine our computational platform with deep experimental expertise to explore target families that have traditionally resisted conventional discovery approaches.
More information will be shared once the initial joint study enters the experimental phase.